In The News
Newest First
All Years
Retinal Physician
August 4, 2026
Rethinking Retinal Fluid in Neovascular AMD
The Ophthalmologist
July 30, 2026
EYP-1901 for Retinal Exudative Diseases: Multi-Mechanism of Action and Phase 2 Clinical Trial Highlights
The Ophthalmologist
May 29, 2026
EYP-1901 for Retinal Exudative Diseases
Ophthalmology 360
March 10, 2026
Tyrosine kinase inhibitors in wet age-related macular degeneration: a new era of durability and disease control
Eyes on Glance
March 3, 2026
EyePoint begins dosing in phase 3 DME trials for DURAVYU
Eyewire+
March 2, 2026
EyePoint Doses First Patients in Phase 3 COMO and CAPRI Trials of Duravyu for DME
Ophthalmology Times
March 2, 2026
EyePoint doses first patient in COMO and CAPRI, phase 3 trials of DURAVYU
Media Mice
March 2, 2026
EyePoint Doses First Patients in Global Phase III Trials of Duravyu for DME
Ophthalmology Management
March 2, 2026